Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-07 in migraine with inadequate response to oral CGRP inhibitors
NCT05550207Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meloxicam + rizatriptan in migraine, sponsored by Axsome Therapeutics, Inc. Primary endpoints: Headache Pain Relief at 2 hours and Absence of Most Bothersome Symptom at 2 hours. Started Aug 2022; status: completed.
02
Drugs
meloxicam + rizatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05550207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550207.